Apelin-12 and its structural analog enhance antioxidant defense in experimental myocardial ischemia and reperfusion

Molecular and Cellular Biochemistry

Volumn 391, Issue 1-2, 2014, Pages 241-250

  Pisarenko, O I ^a   Lankin, V Z ^a   Konovalova, G G ^a   Serebryakova, L I ^a   Shulzhenko, V S ^a   Timoshin, A A ^a   Tskitishvili, O V ^a   Pelogeykina, Yu A ^a   Studneva, I M ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Antioxidant defense; Apelin 12; Its structural analog; Myocardial ischemia reperfusion injury; Rat heart

Indexed keywords

APELIN; APELIN 12; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE KINASE MB; GLUTATHIONE PEROXIDASE; HYDROXYL RADICAL; LACTATE DEHYDROGENASE; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 5,5-DIMETHYL-1-PYRROLINE-1-OXIDE; AMINE OXIDE; ANTIOXIDANT; APELIN-12 PEPTIDE; BIOLOGICAL MARKER; SIGNAL PEPTIDE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; CORONARY REPERFUSION; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EXPERIMENTAL MYOCARDIAL ISCHEMIA; HEART FUNCTION; HEART INFARCTION SIZE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN STRUCTURE; RAT; REPERFUSION INJURY; UPREGULATION; ANESTHESIA; ANIMAL; BLOOD; CHEMISTRY; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; HEART MUSCLE; IN VITRO STUDY; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PATHOPHYSIOLOGY; PERFUSION; WISTAR RAT;

RATTUS;

ANESTHESIA; ANIMALS; ANTIOXIDANTS; BIOMARKERS; CATALASE; CREATINE KINASE, MB FORM; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; ELECTRON SPIN RESONANCE SPECTROSCOPY; GLUTATHIONE PEROXIDASE; IN VITRO TECHNIQUES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; L-LACTATE DEHYDROGENASE; MALE; MALONDIALDEHYDE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PERFUSION; RATS, WISTAR; RECOVERY OF FUNCTION; SUPEROXIDE DISMUTASE;

EID: 84900800981     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2008-4     Document Type: Article

References (41)

1. Ferdinandy P, Schulz R, Baxter G (2007) Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 9:418-458
2. Kleinz MJ, Davenport AP (2005) Emerging roles of apelin in biology and medicine. Pharmacol Therap 107:198-211
3. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, Osmond DH, George SR, O'Dowd BF (2000) Characterization of apelin, the ligand for the APJ receptor. J Neurochem 74:34-41
4. Kunduzova O, Alet N, Delesque-Touchard N, Millet L, Castan-Laurell I, Muller C et al (2008) Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes. FASEB J 22:4146-4153
5. Japp AG, Cruden NL, Amer DA, Li VK, Goudie EB, Johnston NR et al (2008) Vascular effects of apelin in vivo in man. J Am Coll Cardiol 52:908-913
6. Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H et al (2002) Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 91:434-440
7. Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CC (2007) Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Bas Res Cardiol 102:518-528
8. Pitkin SL, Maguire JJ, Bonner TI, Davenport AP (2010) International union of basic and clinical pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev 62:331-342
9. Lee DK, George SR, O'Dowd BF (2006) Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci 27:190-194
10. Japp AG, Newby DE (2008) The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 75:1882-1892
11. Jia YX, Lu ZF, Zhang J, Pan CS, Yang JH, Zhao J, Yu F, Duan XH, Tang CS, Qi YF (2007) Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides 28:2023-2029
12. Dai T, Ramirez-Correa G, Gao WD (2006) Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol 553:222-228
13. Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H (2000) Apelin peptides block the entry of human immunodeficiency virus (HIV). FEBS Lett 473:15-18
14. Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J (2000) Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. J Virol 4:11972-11976
15. Pisarenko OI, Shulzhenko VS, Pelogeykina YuA, Studneva IM, Khatri DN (2010) Apelin-12 improves metabolic and functional recovery of rat heart after global ischemia. Health 2:927-934
16. Pisarenko OI, Serebryakova LI, Studneva IM, Pelogeykina YuA, Tskitishvili OV, Bespalova ZhD, Sidorova MV, Az'muko AA, Khatri DN, Pal'keeva ME, Molokoedov AS (2013) Effects of structural analogues of apelin 12 in acute myocardial infarction in rats. J Pharmacol Pharmacother 4:198-203
17. Weir RA, Chong KS, Dalzell JR, Petrie CJ, Murphy CA, Steedman T et al (2009) Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail 11:551-558
18. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J et al (2010) Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 121:1818-1827
19. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J et al (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277:14838-14843
20. Pisarenko OI, Shulzhenko VS, Pelogeykina YuA, Studneva IM (2012) Attenuation of myocardial ischemia and reperfusion injury by novel analogues of apelin-12. Int J Pharmaceut Biomed Res 3:16-21
21. Rastaldo R, Cappello S, Folino A, Berta GN, Sprio AE, Losano G et al (2011) Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. Am J Physiol Heart Circ Physiol 300:H2308-H2315
22. Pisarenko OI, Pelogeykina YA, Shulzhenko VS, Studneva IM (2012) Nitric oxide synthase mediates the apelin-induced improvement of myocardial postischemic metabolic and functional recovery. Open J Mol Integ Physiol 2:1-7
23. Zeng XJ, Zhang LK, Wang HX et al (2009) Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 30:1144-1152
24. Jia YX, Pan CS, Zhang J et al (2006) Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept 133:147-154
25. Foussal C, Lairez O, Calise D et al (2010) Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Lett 584:2363-2370
26. Tosaki A, Blasig IE, Pali T, Ebert B (1990) Heart protection and radical trapping by DMPO during reperfusion in isolated working rat hearts. Free Radic Biol Med 8:363-372
27. Lowry OH, Rosebrough NJ, Farr AI, Randall RJ (1951) Protein measurements with the Folin phenol reagent. J Biol Chem 193:265-275
28. Beauchamp C, Fridovich I (1971) Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Analyt Biochem 44:276-287
29. Beers RF, Sizer IW (1952) A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem 95:133-140
30. Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte peroxidase. J Lab Clin Med 2:158-169
31. Lankin VZ, Konovalova GG, Tikhaze AK, Nedosugova LV (2012) The effect of natural dicarbonyls on activity of antioxidant enzymes in vitro and in vivo. Biomed Chem 6:81-86
32. Kappusamy P, Zwier JL (1989) Characterization of free-radical generation by xanthine oxidase. Evidence for hydroxyl radical generation. J Biol Chem 264:9880-9884
33. Murphy E, Steenbergen Ch (2008) Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 88:581-609
34. Dhalla NS, Elmoselhi AB, Hata T, Makino N (2000) Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res 47:446-456
35. Halestrap AP, Pasdois P (2009) The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta 1787:1402-1415
36. Rohilla A, Kushnoor N, Kushnoor A (2012) Myocardial ischemia reperfusion injury-pathogenesis and prevention. Int J Res Pharmaceut Biomed Sci 3:929-934
37. Wink DA, Hanbauer I, Krishna MC, DeGraff W, Gamson J, Mitchell JB (1993) Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA 90:9813-9817
38. O'Donnell VB, Chumley PH, Hogg N, Bloodsworth A, Darley-Usmar VM, Freeman BA (1997) Nitric oxide inhibition of lipid peroxidation: kinetics of reaction with lipid peroxyl radicals and comparison with alpha tocopherol. Biochemistry 36:15216-15223
39. Forstermann U, Munzel T (2006) Endothelial nitric oxide synthase in vascular disease from marvel to menace. Circulation 113:1708-1714
40. Frank S, Zacharowski K, Wray GM, Thiemermann CH, Pfeilschifter J (1999) Identification of copper/zinc superoxide dismutase as a novel nitric oxide-regulated gene in rat glomerular mesangial cells and kidneys of endotoxemic rats. FASEB J 13:869-882
41. Husain K, Hazelrigg SR (2002) Oxidative injury due to chronic nitric oxide synthase inhibition in rat: effect of regular exercise on the heart. Biochim Biophys Acta 1587:75-82